Not medical advice. Talk to your provider before using any peptide. Full disclaimer
Ziconotide (Prialt)
Also known as: Prialt, omega-conotoxin MVIIA, SNX-111
A cone snail venom turned FDA-approved painkiller. Ziconotide (brand name Prialt) is a synthetic 25-amino-acid copy of omega-conotoxin MVIIA, approved in December 2004 for severe chronic pain that nothing else can touch. It blocks N-type calcium channels (Cav2.2) at the spinal cord level, stopping pain signals without binding a single opioid receptor. No tolerance builds over years of continuous use; a 2025 meta-analysis of 23 studies (n=1,531) confirmed a mean pain reduction of 22.54 points versus placebo. The catch is delivery. Ziconotide requires continuous intrathecal infusion through a surgically implanted pump, and psychiatric side effects forced discontinuation in roughly half of real-world patients within two years.
What Is Ziconotide (Prialt)?
A 2025 meta-analysis pooling 23 studies and 1,531 patients landed on a mean pain reduction of 22.54 points versus placebo (p=0.002)[1]. That is the most current aggregate number for ziconotide, an FDA-approved peptide derived from Pacific cone snail venom.
Ziconotide (Prialt, omega-conotoxin MVIIA, CAS 107452-89-1) is a synthetic 25-amino-acid peptide with three disulfide bonds. The FDA approved it in December 2004 for severe chronic pain in patients who have failed or cannot tolerate other analgesic options, including intrathecal morphine.
The mechanism is selective Cav2.2 calcium channel blockade at the spinal cord dorsal horn. By physically occluding these channels on nociceptive nerve terminals, ziconotide prevents release of glutamate, CGRP, and substance P. Pain signals stop before reaching the brain. No opioid receptors are involved, so respiratory depression and tolerance are absent.
Three important RCTs built the approval case. Study 96-002 (Wallace et al.)[2] showed 31.2% mean pain reduction versus 6.0% for placebo in 255 patients. Study 301 (Rauck et al.)[3] confirmed efficacy with slower titration in 220 patients. A long-term open-label extension tracked 644 patients over 350 patient-years of sustained relief (Wallace et al.)[4].
Real-world outcomes tell a more complicated story. The PRIZM registry (n=93) recorded about 50% of patients achieving 30% or greater pain reduction at 12 months. Psychiatric side effects, including hallucinations (12%), psychosis (1%), and insidious cognitive decline, drove high discontinuation rates. Only about 4 of 15 patients remained on therapy at two years in one cohort. The 2024 PACC guidelines now recommend starting at 0.5 to 1.0 mcg/day, well below the FDA label's 2.4 mcg/day, because slower titration dramatically reduces CNS adverse events.
How Ziconotide (Prialt) Works
Three disulfide bonds lock ziconotide into a rigid three-dimensional structure. That shape is what makes it fit the Cav2.2 calcium channel pore like a plug. The peptide binds the extracellular surface of the alpha-1B subunit and physically blocks calcium ions from flowing through.
Cav2.2 channels sit densely on nociceptive nerve terminals in laminae I and II of the spinal cord dorsal horn. When calcium can't enter those terminals, vesicular release of excitatory neurotransmitters stops. Glutamate, CGRP, and substance P all stay locked in their presynaptic vesicles. The first central synapse in the pain pathway goes quiet.
Selectivity is the pharmacological headline. Ziconotide has zero affinity for mu, delta, or kappa opioid receptors. It also ignores adrenergic, serotonin, dopamine, and GABA receptors. This explains why opioid side effects (respiratory depression, constipation, escalating tolerance) simply don't occur. There is no receptor downregulation or compensatory upregulation pathway with Cav2.2 blockade; tolerance does not develop over months or years.
The same Cav2.2 channels also exist in supraspinal brain regions that regulate cognition, mood, and motor function. Blocking them there produces the dose-limiting neuropsychiatric toxicity: confusion, hallucinations, memory impairment, and psychosis. That overlap between therapeutic target and toxicity target creates the narrow therapeutic window that makes ziconotide so difficult to dose.
Ziconotide (Prialt) Benefits
- Ziconotide benefits center on non-opioid analgesia for the most refractory chronic pain cases.
- Zero tolerance development over years of continuous therapy. Unlike intrathecal opioids, dose requirements stay flat indefinitely because Cav2.2 blockade has no receptor desensitization pathway.
- Pain reduction of 22.54 points versus placebo across 1,531 patients in a 2025 meta-analysis (Picañol et al.)[1].
- No respiratory depression, no constipation, no physical dependence. Stopping abruptly causes pain return, not opioid withdrawal.
- Study 96-002 (n=255) recorded 31.2% mean pain reduction with rapid titration [2]. Study 301 (n=220) confirmed efficacy under slow titration [3].
- Sustained long-term relief confirmed in a 644-patient open-label extension spanning 350 patient-years [4].
- PRIZM real-world registry showed approximately 50% of patients reaching 30% or greater pain relief at 12 months, holding without dose escalation.
Ziconotide (Prialt): Science vs Community Consensus
FDA-approved (2004) for severe refractory chronic pain via continuous intrathecal infusion.
Read the evidence (key study, limitations)
Three pivotal RCTs established efficacy. 2025 meta-analysis (n=1,531, 23 studies) confirmed mean pain reduction of −22.54 points vs placebo (p=0.002). No pharmacological tolerance. Serious AE rate 17.85% (2.63× placebo). Confined to tertiary pain management settings requiring surgical pump implantation.
Picañol et al. Pain Rep 2025 (PMID 41255849): meta-analysis 23 studies n=1,531; also SPIDOL RCT protocol (Trials 2024, PMID 39244617) for SCI neuropathic pain.
Pivotal RCTs used faster titration than current clinical best practice; high AE-driven dropout rates inflate discontinuation figures; intrathecal-only delivery severely limits applicability; real-world PRIZM registry shows ~50% ≥30% responder rate at 12 months, lower than RCT estimates.
Mixed-to-negative overall sentiment (Drugs.com 4.3/10, 27% positive, 45% negative).
Read the reports (what users report 3, common issues 5)
Those who tolerate it describe meaningful, sustained relief. Most negative reports center on severe CNS adverse effects. High real-world discontinuation: only ~4/15 patients still on drug at 2 years in one cohort.
- Non-opioid analgesia: no tolerance, no respiratory depression, no physical dependence or withdrawal
- Meaningful sustained pain relief for truly refractory patients (CRPS, FBSS, cancer pain) who have failed all other options
- Long-term efficacy without dose escalation, unlike intrathecal opioids
- Severe cognitive impairment: memory loss, word-finding difficulty, confusion, often insidious in onset
- Hallucinations, psychosis, depression; psychiatric AEs can appear weeks after dose change
- Invasive delivery requiring surgical pump implantation under specialist care
- Very high real-world discontinuation rate; many patients cannot tolerate effective analgesic doses
- Recurrent psychiatric AEs on rechallenge documented (PMID 40511848)
Both science and community confirm analgesic efficacy for refractory pain. Divergence on tolerability: clinical trials underestimate real-world CNS AE burden and discontinuation rates. The 2024 PACC guideline shift to 0.5 mcg/day starting dose (vs. FDA label 2.4 mcg/day) reflects this community-driven understanding that slower titration dramatically improves real-world tolerability.
Ziconotide (Prialt) Dosage Guide
| Level | Dose / Injection | Frequency |
|---|---|---|
| Beginner | 2.4 mcg | Daily |
| Moderate | 9.6 mcg | Daily |
| Aggressive | 19.2 mcg | Daily |
Ziconotide ships as a pre-filled solution, not a lyophilized powder. No reconstitution with bacteriostatic water is needed. The two concentrations are 25 mcg/mL and 100 mcg/mL.
Delivery math for the 25 mcg/mL formulation in a 20 mL vial: 500 mcg total per vial. At a maintenance dose of 5 mcg/day, that is a 100-day supply per pump refill. The 100 mcg/mL concentration must be diluted with preservative-free normal saline (not bacteriostatic water) when used in external pumps.
The FDA label says you can start at 2.4 mcg/day. Most pain specialists don't anymore. The 2024 PACC consensus guidelines recommend 0.5 to 1.0 mcg/day with increases no larger than 0.5 mcg/day per week. That slower ramp cuts psychiatric and cognitive side effects dramatically compared to the FDA-label titration speed.
Your pump refill schedule depends on concentration, flow rate, and reservoir size. Typical intervals run every 1 to 3 months. Every refill visit should include cognitive screening, psychiatric assessment, orthostatic blood pressure, and CK levels.
Cycling
Ziconotide is used as continuous long-term therapy delivered via intrathecal pump, not cycled. Treatment is maintained indefinitely as long as the patient derives analgesic benefit and tolerates the medication. Dose adjustments are made gradually: no more than 2.4 mcg/day increases, no more frequently than 2-3 times per week. If discontinued, no taper is required as there is no physical dependence or withdrawal syndrome. Treatment may be interrupted or discontinued if psychiatric symptoms, cognitive impairment, or elevated CK levels occur.
No cycling protocol is used. Ziconotide acts via direct Cav2.2 calcium channel occlusion with no receptor internalization, downregulation, or compensatory upregulation pathway: pharmacological tolerance does not develop. Treatment is continuous and indefinite. Dose adjustments (reductions) manage side effects; abrupt discontinuation is safe if required (no withdrawal syndrome). No on/off cycling confers any clinical benefit.
- No cycling required: absence of tolerance is a defining pharmacological advantage
- Dose reduction (not cessation) is the first-line approach to managing CNS adverse effects
- Abrupt discontinuation is safe (no opioid-like withdrawal) but causes immediate pain return
Or use the universal Peptide Calculator for any peptide.
Ziconotide (Prialt) Protocols by Goal
Expected: ≥30% pain reduction in ~50% of patients at 12 months (PRIZM real-world); −22.54 mean VAS/NRS reduction vs placebo in meta-analysis; 31.2% mean pain reduction in pivotal Study 96-002 (rapid titration arm)
Monitor: CK every 2 weeks for first month, then monthly. MMSE or MoCA at every visit (baseline required). Psychiatric assessment each visit. Orthostatic BP at each pump refill.
How to Inject Ziconotide (Prialt)
- 1Step 1
Ziconotide requires a Medtronic SynchroMed II implantable intrathecal pump or an external microinfusion device with intrathecal catheter. This is not a subcutaneous, intravenous, or epidural medication.
- 2Step 2
A qualified healthcare provider fills the pump reservoir under strict sterile conditions. The 25 mcg/mL solution can go in undiluted. The 100 mcg/mL solution gets diluted with preservative-free 0.9% NaCl to the target concentration.
- 3Step 3
Starting dose is 0.5 to 1.0 mcg/day per 2024 PACC guidelines (or up to 2.4 mcg/day per the FDA label). The pump delivers this continuously over 24 hours, not as a bolus. At 1.0 mcg/day, the pump flow rate is approximately 0.042 mcg/hour.
- 4Step 4
Titration: increase by no more than 0.5 mcg/day per week (PACC preferred) or 2.4 mcg/day no more than 2 to 3 times per week (FDA maximum titration rate). Each dose adjustment requires a clinical visit.
- 5Maximum recommended dose is 19.2 mcg/day (0.8 mcg/hour)
Most patients find an effective maintenance dose between 2 and 9.6 mcg/day; the PRIZM registry median landed around 5.5 to 7.2 mcg/day.
- 6Step 6
Monitoring at every visit: MMSE or MoCA for cognitive function, psychiatric screening, orthostatic blood pressure. CK levels every 2 weeks for the first month, then monthly. Any new psychiatric symptom triggers a dose hold.
- 7Storage: refrigerate at 2 to 8 degrees Celsius
Undiluted vials can sit at room temperature (up to 25 degrees Celsius) for up to 14 days. Once in the pump, use within 84 days refrigerated or 40 days at body temperature.
Ziconotide (Prialt) Stacking Protocols
Works With
Most studied IT combination with ziconotide; complementary mechanisms (opioid + Cav2.2 blockade); used off-label for refractory cancer and non-cancer pain. Admixture stability confirmed up to ~20 days.
Combination IT pump; individual doses titrated independently. Admixture prepared by pharmacy.
Complementary mechanism (alpha-2 adrenergic); good admixture stability (~90% at 60 days at clonidine 2 mcg/mL + ziconotide). Preferred combination for neuropathic pain per PACC.
Clonidine 2 mcg/mL + ziconotide in combination IT pump; monitor for additive hypotension.
Alternative to morphine for opioid-intolerant patients; case reports in spinal cord injury neuropathic pain (PMID 17310258).
Avoid
Additive CNS depression: increased dizziness, confusion, somnolence. FDA-labeled drug interaction.
Increased risk of psychiatric AEs and depressed consciousness when combined with ziconotide. FDA-labeled interaction.
Patients on diuretics are at higher risk of depressed level of consciousness per FDA label.
Confound mandatory CK monitoring; may amplify rhabdomyolysis risk signal. Use with caution and increased CK monitoring frequency.
Estimated Cost
Pricing updated 2026-04-09
Ziconotide (Prialt) Side Effects
Black Box Warning: severe psychiatric symptoms and neurological impairment. This is the lead safety concern, not a footnote. Hallucinations hit 12% of trial patients. Psychosis occurred in 1%. Depression with suicidal ideation has been reported. Documented cases of psychiatric recurrence on rechallenge exist [5], meaning once ziconotide triggers psychosis, restarting it is not safe.
Cognitive impairment is the most insidious problem. Word-finding difficulty, memory loss, and confusion affected 7 to 22% of patients in clinical trials. The onset can be gradual enough that patients or families don't recognize the decline for weeks. Formal cognitive screening (MMSE or MoCA) at every visit catches what casual conversation misses. Any new cognitive symptom within weeks of a dose increase should be attributed to ziconotide until proven otherwise.
Dizziness was the single most common adverse event at 47%. Nausea reached 30%. Confusion hit 33%. Somnolence affected 22%. Abnormal gait (14%), nystagmus (8%), and visual disturbances also appeared in important trials. Most of these track directly with dose; slower titration per the 2024 PACC guidelines (0.5 mcg/day increases weekly instead of the FDA-label rate) substantially reduces incidence.
CK elevation occurred in 10 to 40% of patients. Levels above 3 times the upper limit of normal require dose reduction or hold. Investigate for rhabdomyolysis symptoms (dark urine, muscle pain) if CK spikes.
Meningitis, both chemical and bacterial, has been reported in patients using external microinfusion devices. Strict aseptic technique during pump refills is non-negotiable.
Postural hypotension, urinary retention, fever, and asthenia round out the profile. The serious adverse event rate across the meta-analysis was 17.85%, roughly 2.6 times the placebo rate.
Contraindications: preexisting psychosis (FDA-labeled), active suicidal ideation, severe untreated depression, spinal canal obstruction, uncontrolled bleeding diathesis, active infection at the pump site, pregnancy (Category C), and breastfeeding. When to seek immediate medical attention: new hallucinations, suicidal thoughts, sudden cognitive decline, high-grade fever with neck stiffness, or dark urine with muscle pain.
Common Issues & Solutions
Cognitive fog / memory impairment: Reduce dose by at least 50% immediately. Do not attribute new cognitive symptoms to the patient's baseline condition without ruling out ziconotide first: timing relative to dose changes is the key discriminator. Symptoms typically resolve within days of dose reduction.
Hallucinations or psychosis: Hold dose escalation; consider dose reduction or discontinuation. If frank psychosis, discontinue immediately. Documented recurrence on rechallenge [5]: do not rechallenge in patients with ziconotide-induced psychosis.
Nausea and dizziness on initiation: Dose-dependent and usually transient. Slow PACC titration (≤0.5 mcg/day/week) substantially reduces incidence vs. FDA-label titration rate. Anti-emetics may help short-term but do not treat the underlying dose issue.
CK elevation >3× ULN: Reduce or hold dose; investigate for clinical signs of rhabdomyolysis (myalgias, dark urine). Do not restart until CK normalizes and cause is clarified. Do not increase statin dose during ziconotide therapy without increased CK monitoring.
Abrupt return of pain (suspected pump failure): Pump malfunction or catheter dislodgement mimics treatment failure: check pump function, catheter integrity, and CSF drug levels before assuming inadequate dose. There is no withdrawal syndrome; abrupt pain return is loss of analgesic coverage, not rebound.
Ask AI about this page
Ask AI for a second opinion on Ziconotide (Prialt) dosing and side effects
Contraindications
- Preexisting history of psychosis (FDA-labeled contraindication)
- Hypersensitivity to ziconotide or any component of the formulation
- Active infection at the microinfusion injection site
- Uncontrolled bleeding diathesis or concurrent anticoagulation with spinal canal risk
- Spinal canal obstruction that impairs CSF circulation
- Active suicidal ideation or severe untreated depression
- Pregnancy (Category C: potential for fetal harm based on animal studies)
- Breastfeeding (unknown excretion in human milk; not recommended)
Drug Interactions
- CNS depressants (benzodiazepines, sedatives, antiepileptics): Additive CNS depression including increased dizziness, confusion, and somnolence; monitor closely and consider dose reduction of concomitant agents
- Intrathecal opioids: Combination not studied in controlled trials and not recommended; potential for additive CNS effects
- Neuroleptics/antipsychotics: Increased risk of psychiatric adverse events and depressed consciousness; use with caution
- Intrathecal clonidine or bupivacaine: May potentiate hypotensive effects of ziconotide
- Drugs that elevate CK (statins, fibrates): May complicate monitoring of CK levels, which is recommended during ziconotide therapy
- Diuretics: Patients taking concomitant diuretics may be at higher risk of depressed levels of consciousness
- Additive CNS depression: increased dizziness, confusion, somnolence. FDA-labeled drug interaction.
Product Quality
FDA-approved pharmaceutical product (Prialt, TerSera Therapeutics). No research-grade, compounded, or gray-market versions exist. Standard pharmaceutical supply chain under hospital/specialty pharmacy controls. Product quality is not a sourcing risk: clinical adverse effects are the dominant risk.
- Verify commercial vial lot number, concentration (25 mcg/mL vs. 100 mcg/mL), and expiration before every pump fill
- Use strictly aseptic technique for all pump refills: bacterial meningitis cases reported with external devices; chemical meningitis risk exists with any IT device
- Dilute 100 mcg/mL concentration only with preservative-free 0.9% NaCl: NOT bacteriostatic water (no reconstitution needed, only dilution for pumps requiring lower concentration)
- Verify admixture stability data when preparing combination IT solutions (e.g., morphine + ziconotide stable ~20 days; clonidine + ziconotide stable ~60 days)
Recommended Monitoring
| Test | When | Target |
|---|---|---|
| Creatine Kinase (CK / CPK) | Every 2 weeks for first month; monthly thereafter | <3× ULN; reduce or hold dose if >3× ULN; investigate clinically for rhabdomyolysis symptoms |
| Cognitive Assessment (MMSE or MoCA) | Baseline before initiation required; every clinical visit during titration and maintenance | Significant decline from individual baseline warrants dose reduction or discontinuation |
| Psychiatric Evaluation | Baseline (mandatory: psychosis is FDA contraindication); every visit; urgently with any new psychiatric symptom | Any new hallucinations, psychosis, or suicidal ideation → dose reduction or discontinuation |
| Blood Pressure (orthostatic) | Each pump refill visit | Not listed |
| CSF Analysis | If fever, headache, or neck stiffness develop: especially in patients with external pump | Not listed |
Rhabdomyolysis risk documented in clinical trials; CK elevation common (10–40% of patients)
Ziconotide-induced cognitive impairment can be insidious; formal baseline enables objective comparison
Black Box Warning: hallucinations (12%), psychosis (1%), depression with suicidal ideation; symptoms can emerge weeks after dose change
Postural hypotension reported; additive risk if combined with IT clonidine, systemic diuretics, or antihypertensives
Chemical meningitis and bacterial meningitis both reported; external devices carry highest risk; requires urgent evaluation and lumbar puncture
Ziconotide (Prialt) Before and After
Intrathecal infusion begins at 2.4 mcg/day (0.1 mcg/hour). Steady-state CSF concentration is approximated within ~24 hours (approximately five half-lives). Some patients may notice early pain relief within hours. Common initial side effects include dizziness, nausea, and somnolence.
Gradual dose escalation in increments of no more than 2.4 mcg/day, no more than 2-3 times per week. Pain relief increases with dose. Cognitive side effects (confusion, memory impairment) and psychiatric symptoms may emerge during this period: careful monitoring is essential.
Most patients reach an effective maintenance dose, typically between 4.8-14.4 mcg/day in clinical practice. In pivotal trials, mean effective doses ranged from 6.9-9.6 mcg/day. CK levels should be monitored every other week.
Sustained analgesia at stable dose. Unlike opioids, tolerance does not develop. Ongoing monitoring for insidious cognitive changes, mood disturbances, and psychiatric symptoms is critical. CK monitoring transitions to monthly.
Long-term maintenance with continued efficacy. Pump refills every 1-3 months depending on concentration and flow rate. Long-term open-label data shows sustained pain relief over 350+ patient-years. Periodic neuropsychological assessment is recommended.
What to Expect
Day 1 to 7 (Initiation): Intrathecal infusion starts at 0.5 to 2.4 mcg/day depending on protocol. CSF steady-state concentration arrives within roughly 24 hours (about five half-lives at 4.6 hours CSF t1/2). Some patients notice partial pain relief within hours. Dizziness (47% in trials), nausea (30%), and somnolence (22%) are the dominant early side effects. Most side effect tolerance improves within the first week.
Weeks 1 to 8 (Titration): Dose climbs in incremental steps. PACC slow titration (0.5 mcg/day increases weekly) is preferred in clinical practice over the faster FDA-label schedule. Psychiatric and cognitive adverse events are most likely to surface or worsen during active escalation. Fast titration produced 53.1% pain reduction in trials but carried very high side effect burden. Community and clinical experience consistently favor the slower approach. Confusion (33%), memory impairment (7 to 22%), nystagmus (8%), abnormal gait (14%), and visual changes are the main concerns during this phase.
Months 2 to 6 (Stabilization): Most patients reach an effective maintenance dose, typically between 2 and 9.6 mcg/day. The PRIZM registry recorded a median of 5.5 to 7.2 mcg/day in real-world use. No tolerance develops, so dose requirements stay stable indefinitely. High discontinuation occurs at this stage from delayed-onset cognitive impairment that patients or families only recognize retrospectively. PRIZM data showed about 50% of patients achieving 30% or greater pain relief at month 12.
Months 6 to 24 and beyond (Long-term Maintenance): Sustained pain relief without dose escalation is the defining advantage over intrathecal opioids. The open-label extension (n=644) confirmed continued efficacy over 350 patient-years. Pump refills run every 1 to 3 months. Long-term users describe it as transformative for refractory pain but acknowledge cognitive costs at higher doses. Real-world attrition is steep; roughly 4 of 15 patients remained on therapy at two years in one cohort. External pump users face ongoing meningitis risk from both chemical and bacterial sources.
Detailed Timeline: Science vs Community
CSF steady-state achieved within ~24 hours (~5 half-lives at 4.6 hr CSF t½). Some patients report early partial pain relief within hours.
Mixed first impressions: some notice relief quickly; many experience prominent side effects (dizziness, nausea, sedation) before meaningful pain benefit. Tolerance to side effects often improves within first week.
Incremental pain reduction with each dose step. Psychiatric and cognitive AEs most likely to emerge or worsen during active titration. Fast titration (FDA-label rate) associated with 53.1% pain reduction but very high AE burden.
PACC slow titration (≤0.5 mcg/day/week) consistently preferred in clinical practice. Patients on rapid titration report high rates of cognitive "fog" and psychiatric symptoms. Many discontinue during this phase.
Most patients reach effective maintenance dose (2–9.6 mcg/day in trials; 2–7 mcg/day real-world). No tolerance development: dose requirements stable indefinitely.
Those who tolerate it report meaningful sustained relief. High discontinuation at this stage due to delayed-onset cognitive impairment that patients or families recognize only retrospectively. PRIZM registry: 50% ≥30% responders at Month 12.
Sustained efficacy without dose escalation: key advantage over intrathecal opioids. Long-term OLE (n=644, 350+ patient-years) confirms continued pain relief. Pump refills every 1–3 months.
Long-term survivors describe it as life-changing for refractory pain but acknowledge significant cognitive cost at higher doses. Real-world attrition: ~4/15 patients still on drug at 2 years in one cohort. External pump users face ongoing meningitis risk.
Pharmacokinetics
Source: FDA prescribing information; Wermeling D et al. J Clin Pharmacol. 2003;43(6):624-36. PMID: 12817525 (median 4.5 h in CSF, range 2.9-6.5 h)
Pharmacokinetics: Active Dose Over Time
t½ = ~4.6 hours (CSF); ~1.3 hours (serum)Disclaimer: This curve is a simplified first-order exponential decay model. Actual pharmacokinetics vary based on injection site, individual metabolism, body composition, and other factors. Half-life values are approximate and based on available preclinical and clinical literature. Many research peptides lack formal human pharmacokinetic studies. This is for educational purposes only, not medical advice.
Molecular Profile
Is Ziconotide (Prialt) Legal?
Ziconotide (Prialt) received FDA approval in December 2004 for the management of severe chronic pain in adult patients who require intrathecal therapy and have failed other treatments. It remains the only FDA-approved selective N-type calcium channel blocker for pain. TerSera Therapeutics currently markets it in the United States.
This is a prescription medication, not a research peptide. No compounded or gray-market versions exist. All supply runs through standard pharmaceutical distribution under hospital and specialty pharmacy controls.
Ziconotide carries a Black Box Warning for psychiatric symptoms and neurological impairment. It is classified as a non-scheduled drug (not a controlled substance) because it has no abuse potential or opioid-like reinforcing effects.
Athletes should note that peptide hormones appear on the WADA prohibited list. Ziconotide is not a hormone, but consult a sports medicine physician and verify current WADA status if competition testing applies.
This content is for educational and informational purposes only. It does not constitute medical advice. Consult a licensed healthcare provider before using any medication.
Who Should Consider Ziconotide (Prialt)
- Patients with severe chronic pain refractory to systemic analgesics and adjunctive therapies
- Individuals intolerant of or refractory to intrathecal morphine
- Patients with severe neuropathic pain (e.g., from spinal cord injury, failed back surgery syndrome)
- Cancer patients with intractable pain who have failed conventional analgesic ladders
- Patients requiring non-opioid intrathecal analgesia due to opioid tolerance or adverse effects
- Adults with chronic pain who already have or are candidates for implanted intrathecal pump systems
Related Peptides
What Changed for Ziconotide (Prialt)
Peptide Schedule Research TeamReviewed Apr 7, 202610 Citations
References
- [1]Efficacy and safety of the Cav2.2 blocker ziconotide in pain: a meta-analysis and systematic review (Picanol et al., Pain Rep 2025) (opens in a new tab)PubMed (opens in a new tab)PubMed
- [2]Intrathecal ziconotide in the treatment of chronic nonmalignant pain: a randomized, double-blind, placebo-controlled clinical trial (opens in a new tab)PubMed (opens in a new tab)PubMed
- [3]A randomized, double-blind, placebo-controlled study of intrathecal ziconotide in adults with severe chronic pain (opens in a new tab)PubMed (opens in a new tab)PubMed
- [4]Intrathecal ziconotide for severe chronic pain: safety and tolerability results of an open-label, long-term trial (opens in a new tab)PubMed (opens in a new tab)PubMed
- [5]Recurrent ziconotide-associated delirium and psychosis: a case report (Noe et al., J Clin Psychopharmacol 2025) (opens in a new tab)PubMed (opens in a new tab)PubMed
Additional References
- Pharmacokinetics and pharmacodynamics of intrathecal ziconotide in chronic pain patients (opens in a new tab)PubMed 12817525PubMed
- Ziconotide: a review of its pharmacology and use in the treatment of pain (opens in a new tab)PubMed 19300539Review
- PRIALT (ziconotide intrathecal infusion): FDA Prescribing Information (opens in a new tab)FDA Label
- SPIDOL study protocol for the assessment of intrathecal ziconotide antalgic efficacy for severe refractory neuropathic pain due to spinal cord lesions (Trials 2024) (opens in a new tab)PubMed 39244617PubMed
- Successful reduction of neuropathic pain via intrathecal hydromorphone and ziconotide combination (Saulino et al., Spinal Cord 2007) (opens in a new tab)PubMed 17310258PubMed
Related Tools
Storage & Stability
Frequently Asked Questions
How popular is Ziconotide (Prialt)?
Niche. A popularity tier (hot, popular, emerging or niche), based on search volume and community activity.
Reddit: 20–50. Community mentions on Reddit: ~20–50 threads (r/chronicpain, r/painmanagement). Open r/chronicpain (opens in a new tab).
478 papers on PubMed, the US library of medical research. Search them on PubMed (opens in a new tab).
Low search interest. A band for how often people search Google for the name each month.
These come from this site's peptide records. They are not live counts.